Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by
Exelixis
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in sev ...
and is under development by
GlaxoSmithKline.
About 10 Phase II clinical trials have been run.
it appears development has been discontinued.
Foretinib is an
inhibitor of the kinase enzymes c-Met
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the ''MET'' gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein i ...
and
vascular endothelial growth factor receptor 2 (VEGFR-2).
See also
*
c-Met inhibitors
*
Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
*
VEGFR inhibitor
*
tyrosine-kinase inhibitor
A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The proteins are activated by adding a phosph ...
References
{{Growth factor receptor modulators
Tyrosine kinase inhibitors
Quinolines
4-Morpholinyl compunds
Cyclopropanes
Fluoroarenes
Abandoned drugs